

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657



Driven by Quality. Inspired by Science.

VLL\SE\032\2026-27

Date: 20.07.2026

B S E Limited, P J Towers, Dalal Street, Mumbai - 400001. Scrip Code : 524394	National Stock Exchange of India Limited, "Exchange Plaza", Bandra, Kurla Complex, Bandra (E), Mumbai – 400051. Trading Symbol: VIMTALABS
--	--

Dear Sir/Madam,

Sub – Outcome of the Board Meeting.**Ref - Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

With reference to the subject cited above, please find enclosed herewith unaudited Financial Results as per Regulation 33 of the SEBI (LODR) Regulations, 2015 for the 1st Quarter ended 30th June 2026 along with Limited Review Report.

The said Financial Results were duly reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, at their respective meetings held today.

The meeting of the Board of Directors of the Company commenced at 10:30 A.M. and concluded at 01:30 P.M.

This is for your information and records.

Thanking you,

For VIMTA LABS LIMITED

Sujani Vasireddi
Company Secretary and Compliance Officer



Encl: as above.

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of VIMTA LABS LIMITED

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of M/s VIMTA LABS LIMITED ('the Company'), for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations').
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 20-07-2026



for GATTAMANENI & CO.
Chartered Accountants
(Firm Regn.No.9303S)

K Haribabu

K. HARIBABU
Partner

ICAI Ms. No.222800
UDIN: 26222800ZPVFJD8876

Vimta Labs Limited

Registered Office

142, IDA Phase II, Cherlapally

Hyderabad-500 051, Telangana, India

T : +91 40 2726 4141

F : +91 40 2726 3657



Driven by Quality. Inspired by Science.

Statement of Unaudited Financial Results for the Quarter Ended June 30, 2026

(Amount in INR millions, except Earnings Per Share)

S. No.	Particulars	Quarter Ended			Year ended
		30 Jun 26 (Unaudited)	31 Mar 26 (Audited)	30 Jun 25 (Unaudited)	31 Mar 26 (Audited)
1	Income from operations				
	(a) Revenue from operations (Refer note no. 5)	1,090.74	1,092.45	975.64	4,072.90
	(b) Other income	38.12	27.51	17.49	89.89
	Total Income	1,128.86	1,119.96	993.13	4,162.79
2	Expenses				
	(a) Cost of materials consumed and testing expenditure	226.27	224.48	187.98	806.73
	(b) Cost of lab setup (Refer note no. 5)	0.45	0.27	0.11	1.20
	(c) Changes in inventories of work-in-progress	-	-	-	-
	(d) Employee benefits expense (Refer note no. 6)	294.20	295.70	278.18	1,144.06
	(e) Finance costs	2.37	3.21	3.15	11.67
	(f) Depreciation & Amortisation expense	125.48	127.51	98.62	437.72
	(g) Other expenses	196.71	178.32	172.47	705.72
	Total Expenses	845.48	829.49	740.51	3,107.10
3	Profit/(Loss) before exceptional items and tax [1-2]	283.38	290.47	252.62	1,055.69
4	Exceptional items				
	Statutory impact of new Labour Codes (Refer note no. 7)	-	-	-	16.16
5	Profit/(Loss) before tax [3-4]	283.38	290.47	252.62	1,039.53
6	Tax expense				
	(a) Current tax	58.14	62.43	67.74	262.37
	(b) Taxes of earlier periods	0.38	-	-	3.11
	(c) Deferred tax (benefit)/expense	14.44	16.91	(4.06)	(1.07)
	Total Tax Expense	72.96	79.34	63.68	264.41
7	Profit/(Loss) for the period (5-6)	210.42	211.13	188.94	775.12
8	Other Comprehensive Income/(expense), net of tax expenses				
	<i>Items that will not be reclassified subsequently to profit or loss :</i>				
	(a) Re-measurements of net defined benefit liability	(0.20)	3.70	(0.10)	(0.78)
	(b) Income tax relating to the items	0.05	(0.93)	0.03	0.20
	Total other comprehensive income/(loss), net of tax	(0.15)	2.77	(0.07)	(0.58)
9	Total Comprehensive Income for the period (comprising Profit/(Loss) and other Comprehensive income for the period [7+8])	210.27	213.90	188.87	774.54
10	Paid-up Equity Share Capital (Face value of Rs.2/- per equity share)	89.34	89.34	89.01	89.34
11	Other Equity				4,479.39
12	Earnings per equity share (EPS) (Face value of Rs.2 per share)				
	(a) Basic (INR)	4.71	4.73	4.25	17.40
	(b) Diluted (INR)	4.66	4.62	4.21	17.20
	(EPS for the quarter ended are not annualised)				



Plot No. 5, Life Sciences Facility, Neovantage Science & Technology Park Private Limited, Shamirpet, Genome Valley, Turkapally Medchal-Malkajgiri, Hyderabad-500 101, Telangana, India. T : +91 40 6740 4040 E : mdoffice@vimta.com URL : www.vimta.com

CIN : L24110TG1990PLC01177

Notes to the results :


1. The above Unaudited financial results for the quarter ended June 30, 2026 have been reviewed and recommended by the Audit Committee and approved by the Board in its meeting held on July 20, 2026.
2. The results for the quarter ended June 30, 2026 were subjected to Limited Review by the statutory auditors of the company. An unmodified report was issued by
3. These Unaudited financial results have been prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and the guidelines issued by the Securities and Exchange Board of India ("SEBI") in this regard.
4. The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS-108 'Operating Segment' and stated that the Company has only one reportable segment namely 'Contract Research and Testing Services'.
5. The company had entered into a Public Private Partnership (PPP) agreement with Food Safety and Standards Authority of India (FSSAI) on June 29, 2021 to setup, operate and transfer (SOT) a National food Testing Laboratory (NFL) in JNPT, Mumbai. In accordance with the provisions of Ind AS 115, this arrangement has been considered as a "Service Concessionaire Arrangement" (SCA) and accordingly, revenue and costs are allocatable between those relating to lab setup services and those relating to operation and maintenance services. Further, the Company has acquired the right to charge the customer for the services to be rendered which has been assessed as an intangible asset.

Revenue from operations and lab setup expenses include ₹ 0.45 million for the quarter ended June 30, 2026, ₹ 0.27 million for the quarter ended March 31, 2026, ₹ 0.11 million for the quarter ended June 30, 2025, ₹ 1.20 million for the year ended March 31, 2026, respectively representing the revenues relating to lab setup services provided under SCA, the costs of fulfilling the contract and the right to charge the customer for the services to be rendered, respectively.

6. a) Pursuant to 'Vimta Labs Employee Stock Option Plan 2021 (VLESOP-2021)', the nomination and remunerations committee has granted 40500 options to the eligible employees during its meeting held on July 20, 2026.

b) In respect of stock options granted pursuant to the Company's stock option plan, the fair value of the options is accounted as employee compensation expense over the vesting period. Consequently, the amount of employee benefits expense includes ₹ 8.46 million for the quarter ended June 30, 2026, ₹ 6.87 million for the quarter ended March 31, 2026, ₹ 15.19 million for the quarter ended June 30, 2025, ₹ 49.86 million for the year ended March 31, 2026 respectively.
7. Pursuant to the implementation of the new labour code effective from 21st November, 2025 by the Government of India, the Company has reassessed the impact of the changes based on actuarial valuation and recognised an incremental impact of past service cost in gratuity amounting to ₹16.16 million, arising primarily from the revision in the definition of wages. Considering its non-recurring nature and quantum involved, past service cost is presented under "exceptional items" in the statement of profit & loss for the year ended March 31, 2026.
8. The company does not have any subsidiary/associate/joint venture entity(ies) during the quarter under review and the comparable periods.
9. The figures of the quarter ended March 31, 2026 are the balancing figures between Audited figures in respect of the financial year ended March 31, 2026 and Unaudited published year to date figures up to the 9 months ended December 31, 2025, which were subjected to limited review by the statutory auditors
10. The previous period figures have been regrouped/rearranged wherever necessary to make it comparable with the current period.

For and on behalf of the Board of Directors of
Vimta Labs Limited
CIN: L24110TG1990PLC011977



Harita Vasireddi
Managing Director
DIN: 00242512

Place : Hyderabad, INDIA
Date : July 20, 2026

